tbuckley/cabot-search huggingface dataset:
Massive Thoracic Extramedullary Hemopoiesis
Authors: Russell B. Hanford, Gilbert F. Schneider, John D. MacGarthy
Journal: New England Journal of Medicine (1960)

TWO patients seen during the past ten years have justified a re-emphasis of the fact that paravertebral masses of hemopoietic tissue in the thorax can develop in hereditary spherocytic anemia. In the 2 cases described below the significance of the anemia had been overlooked, and the patients were referred to us for investigation of what was assumed to be primary neoplasms in the thorax. In both cases successful therapy depended upon identification of the primary process, followed by splenectomy.Case ReportsCase 1. A.W., a 61-year-old laborer from a small community in central Washington, was referred to the thoracic surgeon . . .
GLOBAL LONGITUDINAL STRAIN IMPROVEMENT POST-TRANSCATHETER AORTIC VALVE REPLACEMENT CORRELATES WITH BASELINE STROKE VOLUME INDEX IN PATIENTS WITH LOW FLOW SEVERE AORTIC STENOSIS REGARDLESS LEFT VENTRICULAR EJECTION FRACTION
Authors: Xiao Zhou, Salim Hayek, Sharon Howell, Patricia Keegan, Vinod Thourani, Vasilis Babaliaros, Stamatios Lerakis
Journal: Journal of the American College of Cardiology (2015)
AB0967 The effect of body mass on the number of osteoarthritis (OA) flares with continuous vs intermittent celecoxib treatment
Authors: G.H. Sands, P. Bhadra, M. Noyes Essex
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Abstract</h3> Hibernation is a mammalian strategy that uses metabolic plasticity to reduce energy demands and enable long-term fasting. Fasting mitigates winter food scarcity but eliminates dietary nitrogen, jeopardizing body protein balance. Here, we reveal gut microbiome-mediated urea nitrogen recycling in hibernating 13-lined ground squirrels (TLGS). Ureolytic gut microbes incorporate urea nitrogen into organic compounds that are absorbed by the host, with the nitrogen reincorporated into the TLGS protein pool. Urea nitrogen recycling is greatest after prolonged fasting in late winter, when urea transporter abundance in gut tissue and urease gene abundance in the microbiome are highest. These results reveal a functional role for the gut microbiome in hibernation and suggest mechanisms by which urea nitrogen recycling contributes to protein balance in other monogastric animals, including humans. <h3>One Sentence Summary</h3> Ground squirrels and their gut symbionts benefit from urea nitrogen recycling throughout hibernation.
Reflecting the Debates of Updating the Prostate Cancer Guidelines
Authors: James L. Mohler
Journal: Journal of the National Comprehensive Cancer Network (2007)

The NCCN Prostate Cancer Clinical Practice Guidelines in Oncology are revised at least annually using teleconferences, and every 3 years, they are examined in greater detail in face-to-face panel meetings.The 2006 face-to-face meeting addressed 5 major issues.To give guidelines users an appreciation for the process used to make the fairly substantial changes in the 2007 Guidelines, this issue of the Journal of the National Cancer Network (JNCCN) includes point/counterpoint manuscripts for 3 of those 5 debates.
P3-04-02: Bevacizumab Treatment Alters Intrinsic Subtypes in a VEGF-Reinforced Xenograft Model of ER-Positive Breast Cancer.
Authors: Y Gökmen-Polar, RA Toroni, C Goswami, KL Sanders, U Sirimalle, R Mehta, L Li, M Ivan, S Badve, GW Sledge
Journal: Cancer Research (2011)

Abstract Background: Anti-vascular endothelial growth factor (anti-VEGF) therapy improves disease-free but not overall survival in metastatic breast cancer. To seek further insight on resistance to anti-VEGF antibody bevacizumab (BEV) at the molecular level, we developed breast cancer xenograft models allowing comparison of tumor response at different time-points. Here we report the gene expression and miRNA analyses of response and non-response to BEV in these models. Methods: MCF-7 cells transfected with control vector (ML20) or VEGF (MV165) were implanted into the mammary fat pads of athymic mice. Tumors from short-term treatment with BEV (3 weeks; Responders to BEV, R) or long-term treatment (8 weeks; Non-Responders, NR) or with vehicle control group (V) were subjected to whole-genome gene expression analysis (Human WG-6v2 Expression Beadchips, Illumina) and miRNA profiling (TaqMan ArrayHuman MicroRNA A+B Cards Set v3.0, Applied Biosystems).Validation of the chosen genes was performed using quantitative real-time RT-PCR (qRT-PCR) and Immunohistochemistry (IHC). Results: Short-term treatment to BEV (3 weeks; 5 mg/kg, i.p./twice weekly) inhibited primary tumor growth significantly in MV165 xenografts compared with vehicle control, whereas BEV treatment did not affect the tumor growth in the ML20 model. MV165 xenografts progressed after 8 weeks of BEV treatment. Gene set enrichment analysis (GSEA) revealed that luminal A-related gene sets were enriched in MV165-R compared to MV165-NR group including DESMEDT (ESR1), SMID_Breast_Cancer_Luminal_A_up, and MASSARWEH_ Tamoxifen_Resistance_ Down. Myoepithelial-specific gene sets were upregulated in both the R and NR groups compared with the vehicle group. qRT-PCR analysis showed that estrogen receptor alpha (ESR1) representative for luminal A decreased significantly in the MV-165-NR group (P=0.001) compared to vehicle. In contrast, Cytokeratin 5 (KRT5) levels increased significantly in both R (P=0.02) and NR (P=0.03) groups. In addition, KRT14 was upregulated in R (P= 0.04) and in NR (P=0.14) group in comparison with the vehicle group, suggesting the upregulation of myoepithelial phenotype specific to BEV treated MV165 model, but not ML20 model. Similar results were obtained by IHC. Consistent with mRNA changes, ESR1 regulated miRNA such as miR-107 (P=0.007) and miRNA important in tamoxifen resistance such as mir-451 (P= 0.0003) were also altered in MV165-NR group compared to vehicle. Conclusion: These results suggest that treatment with BEV may alter the intrinsic subtypes in the presence of VEGF expression. These data may help to explain the variable results to anti-VEGF therapy based on the duration of BEV treatment. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P3-04-02.
Abstract 5094: Genome-wide molecular profiles of undifferentiated pleomorphic sarcoma and leiomyosarcomas
Authors: Sara Martoreli Silveira, Rolando Andre Rios Villaces, Isabela Werneck Cunha, Ademar Lopes, Silvia Regina Rogatto
Journal: Cancer Research (2012)

Abstract Malignant soft-tissue sarcomas are a heterogeneous group of mesenchymal cancers accounting for 1% of all malignant tumors in adult. These tumors are classified according their differentiation status. Undifferentiated high-grade spindle/pleomorphic sarcoma (UPS) presents a clinically aggressive behavior with frequent development of distant metastases and recurrence after surgery. The genome profile of 20 UPS and 17 leiomyossarcomas (LMS) was evaluated by array CGH and correlated with the clinical course and histopathological findings. Array CGH was done using the Human 44K Agilent oligoarrays according to manufacturer's instructions. Data were extracted using the Feature Extraction software, version 10.7, and analyzed by Nexus Software v 6.0 (BioDiscovery), with a FASST2 (Fast Adaptive States Segmentation Technique 2) algorithm. DNA copy number alterations were compared with a reference dataset of healthy Brazilian individuals and with Database of Genomic Variants. DNA from UPS presented 1406 CNAs and from LMS showed 625 CNAs. However, the genomic profile revealed striking similarities between both tumors that were indistinguishable by unsupervised hierarchical cluster analysis. In UPS samples, genomic gains were mainly found on chromosomes 1 and 7 (79 and 65 events, respectively), while recurrent losses encompassing chromosomes 1 and 12 (49 and 43 events, respectively). Recurrent gains on chromosomes 5 and 17 (28 and 30 events, respectively) and losses on chromosomes 2 and 10 (29 and 28 events, respectively) were frequently found in LMS. Gains on 2q11.1-q11.2 (P=0.031) and losses on 21p11.1 (P=0.001) were significantly detected in patients with UPS alive with the disease and alive without the disease, respectively. In LMS, gains in 1q and 11q (P=0.02 and P=0.043), as well as losses in 17q25 (P=0.05) were associated with tumor recurrence. Non-supervised hierarchical clustering revealed three groups. Cluster 2 was characterized by retroperitoneal tumors (P=0.04) and cluster 3 included both, LMS and UPS, from extremities (P=0.032). None exclusive alteration was verified for cluster 1. In addition, losses on 3p12.1-p11.2 found in UPS and gains on 1q21.3 and 11q13.2-q13.3 in LMS were associated significantly with reduced patient survival (P&amp;lt;0.05). These data suggest a very complex interplay between UPS and LMS, providing new hints about the pathobiology of these tumors. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5094. doi:1538-7445.AM2012-5094
Cautious Optimism for Offspring of Women with Cancer during Pregnancy
Authors: Michael F. Greene, Dan L. Longo
Journal: New England Journal of Medicine (2015)

Fortunately, cancer rarely complicates pregnancy, with a cancer diagnosis in approximately 1 of 1000 pregnant women. Thus, for busy obstetrical care providers who deliver 125 babies per year, the odds that they will have a patient with cancer are about one in every 8 years. Given the variety of cancers that are diagnosed during pregnancy, it is unlikely that most obstetrical care providers will see more than two or three cases of any given type of maternal cancer in their careers. For similar reasons, most oncologists have limited familiarity with cancers that occur during pregnancy, as do most pediatricians who . . .
Examination of overall treatment effect and the proportion attributable to contextual effect in osteoarthritis: meta-analysis of randomised controlled trials
Authors: Kun Zou, Jean Wong, Natasya Abdullah, Xi Chen, Toby Smith, Michael Doherty, Weiya Zhang
Journal: Annals of the Rheumatic Diseases (2016)

Objective To examine the overall treatment effect and the proportion attributable to contextual effect (PCE) in randomised controlled trials (RCTs) of diverse treatments for osteoarthritis (OA). Methods We searched Medline, Embase, Central, Science Citation Index, AMED and CINAHL through October 2014, supplemented with manual search of reference lists, published meta-analyses and systematic reviews. Included were RCTs in OA comparing placebo with representative complementary, pharmacological, non-pharmacological and surgical treatments. The primary outcome was pain. Secondary outcomes were function and stiffness. The effect size (ES) of overall treatment effect and the PCE were pooled using random-effects model. Subgroup analyses and meta-regression were conducted to examine determinants of the PCE. Results In total, 215 trials (41 392 participants) were included. The overall treatment effect for pain ranged from the smallest with lavage (ES=0.46, 95% CI 0.24 to 0.68) to the largest with topical non-steroidal anti-inflammatory drugs (ES=1.37, 95% CI 1.19 to 1.55). On average, 75% (PCE=0.75, 95% CI 0.72 to 0.79) of pain reduction was attributable to contextual effect. It varied by treatment from 47% (PCE=0.47, 95% CI 0.32 to 0.70) for intra-articular corticosteroid to 91% (PCE=0.91, 95% CI 0.60 to 1.37) for joint lavage. Similar results were observed for function and stiffness. Treatment delivered by needle/injection and other means than oral medication, longer duration of treatment, large sample size (≥100 per arm) and public funding source were associated with increased PCE for pain reduction. Conclusions The majority (75%) of the overall treatment effect in OA RCTs is attributable to contextual effects rather than the specific effect of treatments. Reporting overall treatment effect and PCE, in addition to traditional ES, permits a more balanced, clinically meaningful interpretation of RCT results. This would help dispel the frequent discordance between conclusions from RCT evidence and clinical experience—the ‘efficacy paradox’.
IMPACT OF PATIENT RACE IN BLOOD PRESSURE CONTROL AFTER RENAL SYMPATHETIC DENERVATION
Authors: Carlos A. Collet, Humberto Casal, Bruno Burger, Juan Munoz, Carlos Calderas, Roberto Correa Bastidas, Nusen Beer, Gabriel Varnagy, Enrique Fermin, Jose Vasquez, Carlos Leon, William Torres Mogollon, Jose Miguel Torres Viera, pedro hidalgo, Victor Rodriguez, simon tovar, Jose Condado
Journal: Journal of the American College of Cardiology (2014)
Case 10-2016
Authors: Ferdinando S. Buonanno, Jeremy D. Schmahmann, Javier M. Romero, Robert S. Makar
Journal: New England Journal of Medicine (2016)

A 22-year-old man with sickle cell disease presented with headache and difficulty speaking after smoking marijuana. He had anomia, apraxia, and alexia and was unable to perform arithmetic. Diagnostic tests were performed, and management decisions were made.
Abstract 1675: Identification of KURO3 overexpressed in high-grade prostate cancer
Authors: Kenji Tamura, Mutsuo Furihata, Hirofumi Satake, Takashi Anchi, Shingo Ashida, Ichiro Yamasaki, Keiji Inoue, Taro Shuin
Journal: Cancer Research (2011)

Abstract Prostate cancer is usually androgen-dependent and responds well to androgen ablation therapy. However, at a certain stage some prostate cancers eventually acquire a castration-resistant phenotype. These cancer cells are originally high-grade and show very poor response to any anticancer therapies. To characterize the molecular features of clinical high-grade prostate cancers, we analyzed gene-expression profiles by genome-wide cDNA microarray combined with microdissection and found dozens of trans-activated genes in clinical high-grade prostate cancers. Among them, we report the identification of a new biomarker, KURO3. We confirmed overexpression of KURO3 in high-grade prostate cancer cells by RT-PCR. Knockdown of KURO3 expression by siRNA in a prostate cancer cell line resulted in a drastic decrease of cell numbers. In contrast, KURO3 overexpression in a prostate cancer cell line promoted cell proliferation. These findings suggest that KURO3 could be involved in aggressive phenotype of prostate cancers, including hormone-resistant prostate cancers, and that it should be a potential molecular target for development of new therapeutics and a diagnostic biomarker for aggressive prostate cancers. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1675. doi:10.1158/1538-7445.AM2011-1675
Breast Cancer Gene Found
Authors: S. Jenks
Journal: JNCI Journal of the National Cancer Institute (1994)

Journal Article Breast Cancer Gene Found Get access Susan Jenks Susan Jenks Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 19, 5 October 1994, Pages 1444–1445, https://doi.org/10.1093/jnci/86.19.1444 Published: 05 October 1994
SAFETY OF VERY LOW LDL-C LEVELS WITH EVOLOCUMAB: AN ANALYSIS OF 5942 PATIENTS FROM PHASE 2 AND 3 AND OPEN-LABEL EXTENSION STUDIES
Authors: Peter P. Toth, Dirk Blom, Erik Stroes, Constantine Djedjos, Ricardo Dent, Yuna Wu, Ransi Somaratne, Magdalena Uhart, Michelle Geller, Scott Wasserman, Marc Sabatine, Robert Giugliano
Journal: Journal of the American College of Cardiology (2016)
Hyperphosphorylation of autoantigenic targets of paraproteins is due to inactivation of PP2A
Authors: Klaus-Dieter Preuss, Michael Pfreundschuh, Natalie Fadle, Evi Regitz, Sybille Raudies, Niels Murwaski, Manfred Ahlgrimm, Joerg Bittenbring, Markus Klotz, Karl-Herbert Schäfer, Gerhard Held, Frank Neumann, Sandra Grass
Journal: Blood (2011)
ASSOCIATION OF HIGH CLOT BURDEN IN PULMONARY EMBOLISM WITH RIGHT HEART STRAIN AND IMMEDIATE ADVERSE CLINICAL EVENTS
Authors: Praveen Hariharan, David Dudzinski, Rachel Rosovsky, Peter MacMahon, Faris Haddad, Ikenna Okechukwu, Blair Parry, Yuchiao Chang, Christopher Kabrhel
Journal: Journal of the American College of Cardiology (2016)
Congress Flooded With Letters for Breast Cancer Awareness Month
Authors: Nancy Volkers
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Congress Flooded With Letters for Breast Cancer Awareness Month Get access Nancy Volkers Nancy Volkers Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 21, 6 November 1991, Page 1534, https://doi.org/10.1093/jnci/83.21.1534 Published: 06 November 1991
AB0585 Clinical Characterization of Cutaneous Single-Organ Vasculitis According to Chapel Hill-2012 Criteria. Study of 60 Patients from A Series of 766 Cutaneous Vasculitis
Authors: J. Loricera, R. Blanco, T. Pina, V. Calvo-Río, F. Ortiz-Sanjuán, M. Santos-Gόmez, J. Rueda-Gotor, L. Άlvarez, M.C. González-Vela, M.A. González-Lόpez, S. Armesto, M. Marcellán, M.A. González-Gay
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Cutaneous vasculitis (CV) encompasses a wide group of entities characterized by skin blood vessels inflammation. Cutaneous single-organ vasculitis (CSOV) was recently defined according to Chapel Hill-2012 criteria as a CV limited to skin. To our knowledge, there is not any published report on CSOV. <h3>Objectives</h3> Our aim was to characterize CSOV from a wide series of CV. <h3>Methods</h3> We study CSOV from a series of 766 patients with CV from a single university center. CSOV was diagnosed according to Chapel Hill-2012 criteria. The following conditions were required: a) a skin biopsy showing characteristic leukocytoclastic vasculitis and b) vasculitis limited to skin. <h3>Results</h3> We study 60 patients (26 women and 34 men) with a mean age ± SD of 55.70±16.25 years who fulfilled the Chapel Hill-2012 definition for CSOV. The main precipitating events were drug intake (26 patients, 52%) and a previous infection (17 patients, 34%). The main clinical manifestations were cutaneous (100%, palpable purpura in 81.7%) and fever (11 cases, 18.33%). The analytical findings were leukocytosis (mean; 13009±1082x10<sup>9</sup>/L) and elevated ESR (mean, 40.2±22.7 mm/1st hour). In most patients pharmacological therapies were not required (73.33%). In the remaining patients the drugs used were nonsteroidal anti-inflammatory drugs (13.3%), corticosteroids (15%), antihistaminic drugs (3.3%) and colchicine (1,7%). After a median follow-up of 4 months [IQR:2-13] a complete recovery was observed in all the cases and relapses were observed in 5 (8.3%) patients. <h3>Conclusions</h3> CSVO according to Chapel Hill-2012 criteria is a benign syndrome. <h3>Acknowledgements</h3> This study was supported by a grant from "Fondo de Investigaciones Sanitarias" PI12/00193 (Spain). This work was also partially supported by RETICS Programs, RD08/0075 (RIER) and RD12/0009/0013 from "Instituto de Salud Carlos III" (ISCIII) (Spain). <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2706
Tumor Content of the Antiapoptosis Molecule Survivin and Recurrence of Bladder Cancer
Authors: Hubert S. Swana, Douglas Grossman, Julian N. Anthony, Robert M. Weiss, Dario C. Altieri
Journal: New England Journal of Medicine (1999)

To the Editor: Transitional-cell carcinoma of the bladder is the fourth most common cancer among American men, with approximately 50,000 new cases and 10,500 deaths from the disease every year. Fif...
Point-of-Care Photomicroscopy of Urine
Authors: Walter P. Mutter, Robert S. Brown
Journal: New England Journal of Medicine (2011)

the steering committee of an imbalance in cancers.They contacted the DSMBs of IMPROVE-IT and SHARP.Merck was not informed of the imbalance.In July 2008, Merck first became aware of the imbalance after database lock and unblinding and provided that information to the SHARP and IMPROVE-IT steering committees, informing them of the need to notify regulators and publicly disclose such information.The clinical trial chairs arranged a metaanalysis of the data, independent of Merck, and reported the findings directly to regulators.
Reply
Authors: Vincent Wai‐Sun Wong, Grace Lai‐Hung Wong, Henry Lik‐Yuen Chan
Journal: Hepatology (2016)

We thank Drs. Sarikaya, Turan, and Celikbilek for their interest in our work. Our recommendation against screening for nonalcoholic fatty liver disease (NAFLD) in patients with suspected or confirmed coronary artery disease was based on several key points.1 First, despite the strong association between NAFLD and coronary artery disease, most such patients died of cardiovascular complications and not hepatocellular carcinoma or cirrhosis. Second, NAFLD did not predict cardiovascular outcomes in patients with already established coronary artery disease. Third, in line with the recommendations of the American Association for the Study of Liver Diseases, we agree that the optimal screening tool is yet to be defined.2 After all, it is the severity of liver disease and not the mere presence of hepatic steatosis that counts. In that regard, the use of noninvasive tests of liver fibrosis as a screening tool deserves further evaluation.3 As for the apparently lower cardiovascular mortality in patients with NAFLD and coronary artery disease, our additional analysis suggests that aggressive treatment of this high-risk group such as the use of statins has probably altered the natural history of disease.4 Patients with NAFLD were more likely to receive statins than those without (91% versus 73%; P < 0.0001), and statin users had much lower risk of death (hazard ratio 0.30, 95% confidence interval 0.20-0.45; P < 0.0001). The importance of proper management of metabolic factors cannot be overemphasized. On the other hand, we agree with Drs. Sarikaya, Turan, and Celikbilek that coronary intervention does not improve survival in patients with stable angina and should be reserved for those with stronger indications. Vincent Wai-Sun Wong, M.D.1,2 Grace Lai-Hung Wong, M.D.1,2 Henry Lik-Yuen Chan, M.D.1,2 1Department of Medicine and Therapeutics 2State Key Laboratory of Digestive Disease The Chinese University of Hong Kong Hong Kong
Customized partially covered biodegradable stent for anastomotic leakage after esophagojejunostomy
Authors: Joan Gornals, Laura Rivas, Humberto Aranda, Monica Miro, Maica Galan
Journal: Endoscopy (2015)

A 73-year-old man underwent a total gastrectomy plus splenectomy for a gastric adenocarcinoma (T3N1M0). At the early postoperative stage, the patient presented an esophagojejunostomy leak (> 1 cm diameter; [Fig. 1 a]). Medical management and endoscopic treatment were considered first. A customized, partially covered biodegradable stent ([Fig. 1 b]) (Ella Stent; ELLA-CS, Hradec Kralove, Czech Republic; diameter 31/25/31 mm, length 110 mm) was successfully placed under fluoroscopic and endoscopic guidance 5 weeks after surgery. At follow-up with endoscopic monitoring at 4 days ([Fig. 1 c, d]), 20 days, and 2 months ([Fig. 1 e]) after stent placement, adherence of each noncovered stent end (proximally and distally) was observed, as was an intrastent fold causing partial obstruction of the stent's lumen. Balloon dilation up to 20 mm was performed without incident, improving the luminal patency of the stent. The patient felt progressively better, and oral feeding was started after barium transit had shown nonleakage of the lumen with resolution of the dehiscence ([Fig. 1 f]). Upper endoscopy 14 weeks later confirmed the total disappearance of the biodegradable stent and sealing of the anastomotic leakage. A granular appearance of the mucosa was identified in the area where the noncovered stent ends had adhered ([Video 1]). The patient had a favorable outcome and he is currently tolerating most kinds of food.